Compare MKS Instruments (MKSI) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MKS Instruments vs Organon & Co. Common Stock — how do they compare? MKS Instruments trades at $230.19 (market cap $16.74B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: MKS Instruments is far larger — about 4.6× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays the higher dividend (0.58%). Which is the better fit depends on your goals — on Pluang, investors hold MKS Instruments for 9 Days and Organon & Co. Common Stock for 0 Days on average.
| MKSI | OGN | |
|---|---|---|
Market Cap | $16.74B | $3.62B |
Volume | 1,685,097 | 2,892,999 |
Sector | Technology | Health |
52-Week High | $444.80 | $13.81 |
52-Week Low | $134.42 | $5.70 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $20.31B | $11.04B |
Dividend Yield | 0.4% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MKSI trades at $247.56, down 0.94% on the day, with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $3.30 exceeding expectations by 13.4%. Revenue growth continues with 2026 projections showing $4.3B and net profit margin expanding to 10.09%. Analyst consensus remains strongly bullish with 82.8% buy ratings and a $404 price target representing 63% upside potential.
The stock presents compelling growth potential driven by earnings momentum and institutional confidence, though near-term technical weakness and margin pressures from facility expansions pose risks. Long-term wafer fabrication equipment demand and ESG initiatives provide strategic tailwinds, but investors should monitor execution on profitability targets amid competitive pressures in the electronics sector.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MKS Instruments
MKS develops instruments, systems, and process control solutions for advanced manufacturing. Its technologies serve semiconductor manufacturing, electronics and packaging, photonics, and specialty industrial applications.
Read more on MKSI →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
